GlobeNewswire by notified

Biotalys Board and Executive Changes

Share

Ghent, BELGIUM , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Press release - regulated information – inside information

Biotalys Board and Executive Changes

Luc Basstanie retires from the Board of Directors

Hilde Revets leaves the organization

Ghent, BELGIUM – 17 September 2021, 07:00 CEST, Biotalys (Euronext - BTLS) (“Biotalys” or “the Company”), an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for a more sustainable and safer food supply, today announces changes in its Board of Directors and its Executive Committee.

Luc Basstanie who has been at the Board of Directors of Biotalys since inception will retire from his Senior Investment role within Agri Investment Fund (AIF), one of the major shareholders of Biotalys, as of 30 September 2021. Luc has informed the Company that he will also retire from his Board position effective 30 September 2021. Luc has been supporting Biotalys over the years with his broad knowledge and experience in agriculture and played an essential role, together with AIF, in the successful IPO of Biotalys in July. Biotalys will continue to work with AIF as a major shareholder of the organization and will initiate a search to identify a new director.

“On behalf of the Board, I would like to thank Luc for his long-term support for Biotalys, which has been instrumental in placing the Company in the strong position it occupies today,” said Simon Moroney, Chairman of the Board.

After several years of collaboration, Hilde Revets, Biotalys’ Chief Scientific Officer, leaves the organization today to pursue new opportunities. Hilde participated in building the AGROBODY Foundry™ platform, leveraging many years of research and development experience in drug discovery & development, especially focusing on antibody technology development. The Company has initiated a search to identify a suitable replacement to lead the Company’s scientific activities. During the transition, Luc Maertens, COO, and Patrice Sellès, CEO, will overview the operations, while relying on Biotalys’ strong scientific team to implement the current plans.

“The Company is grateful to Hilde for all her work, which has helped to establish it as a leader in applying novel technology to crop protection. We wish her the very best for the future,” commented Simon Moroney, Chairman of the Board.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since 2 July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact

Toon Musschoot, Head of IR & Communication

T: +32 (0)9 274 54 00

E: Toon.Musschoot@biotalys.com

Consilium Strategic Communications

Amber Fennell

T: +44 (0)203 709 5700

E: Biotalys@consilium-comms.com

Important Notice

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Completion of capital reduction in Spar Nord Bank A/S26.4.2024 08:45:00 CEST | Press release

Company announcement no. 28 As stated in company announcement no. 22, it was decided at Spar Nord Bank A/S’ ordinary general meeting on 19 March 2024 to reduce the company’s share capital by DKK 27,645,950 nominal value divided into 2,764,595 shares of DKK 10 through the cancellation of treasury shares. The capital reduction was published via the Danish Business Authority’s IT system on 26 March 2024. The statutory notice period has expired with no claims received. The capital reduction has been finally registered with the Danish Business Authority on 25 April 2024. After the capital reduction, the share capital of Spar Nord Bank A/S amounts to DKK 1,177,020,310 nominal value divided into shares of DKK 10 each. Pursuant to section 32 of the Danish Capital Markets Act, we hereby announce that the company’s total share capital and total number of voting rights amount to: Share capital (nominal value): DKK 1,177,020,310 Number of voting rights: 117,702,031 Please direct any questions rega

Gennemførelse af kapitalnedsættelse i Spar Nord Bank A/S26.4.2024 08:45:00 CEST | pressemeddelelse

Selskabsmeddelelse nr. 28 Som oplyst i selskabsmeddelelse nr. 22 blev det på Spar Nord Bank A/S’ ordinære generalforsamling den 19. marts 2024 besluttet at nedsætte selskabets aktiekapital med nominelt DKK 27.645.950 fordelt i 2.764.595 aktier à DKK 10 ved annullation af egne aktier. Offentliggørelse af kapitalnedsættelsen har fundet sted i Erhvervsstyrelsens it-system den 26. marts 2024. Proklamafristen er udløbet uden indsigelser. Kapitalnedsættelsen er endeligt registreret den 25. april 2024 hos Erhvervsstyrelsen. Efter kapitalnedsættelsen udgør aktiekapitalen i Spar Nord Bank A/S nominelt DKK 1.177.020.310 fordelt i aktier à DKK 10. I henhold til §32 i lov om kapitalmarkeder oplyses det hermed, at selskabets samlede aktiekapital og samlede antal stemmerettigheder er opgjort til: Aktiekapital (nominelt): DKK 1.177.020.310 Antal stemmerettigheder: 117.702.031 Spørgsmål i forbindelse med denne meddelelse kan rettes til undertegnede på 96 34 42 36. Venlig hilsen Rune Brandt Børglum IR-

Adevinta (ASA) publishes its 2023 Annual Report26.4.2024 08:30:00 CEST | Press release

Oslo, 26 April 2024 – Adevinta ASA today released its 2023 Annual Report, available here. A printed copy may be obtained free of charge upon written request to: ir@adevinta.com. Reflecting on 2023, Antoine Jouteau, CEO, said: “Over the past year, we have made significant progress on redesigning our operating model, verticalising our organisation in line with our Growing At Scale strategy and successfully completing our portfolio optimisation. We have achieved strong financial and operational performance in 2023 and continued to deliver against our targets, despite the tough macroeconomic environment. Following the divestment of our Hungarian classifieds business, our portfolio is now centred around our core European markets of France, Germany, Spain, Italy and Benelux, complemented by Canada and our joint ventures. We are delivering significant growth in our Mobility, Re-Commerce and Real Estate & Emerging verticals, substantiating our focus in these areas. By putting technology and pr

PCI Biotech Holding ASA - Annual Report 202326.4.2024 08:08:19 CEST | Press release

Oslo, Norway, April 26, 2024. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, rs@pcibiotech.no, Mobile: +47 940 05 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments 2023 Annual Report PCI Biotech Holding ASApcibiotechholdingasa-2023-12-31-en

Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding

STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil

HiddenA line styled icon from Orion Icon Library.Eye